Rabasco Meneghetti, Asier
Zwanenburg, Alex
Linge, Annett
Lohaus, Fabian
Grosser, Marianne
Baretton, Gustavo B.
Kalinauskaite, Goda
Tinhofer, Ingeborg
Guberina, Maja
Stuschke, Martin
Balermpas, Panagiotis
von der Grün, Jens
Ganswindt, Ute
Belka, Claus
Peeken, Jan C.
Combs, Stephanie E.
Böke, Simon
Zips, Daniel
Troost, Esther G. C.
Krause, Mechthild
Baumann, Michael
Löck, Steffen
Funding for this research was provided by:
Helmholtz-Zentrum Dresden - Rossendorf e. V.
Article History
Received: 27 May 2022
Accepted: 23 September 2022
First Online: 6 October 2022
Competing interests
: M.B., CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards and boards of trustees. M.B. confirms that there is no conflict of interest for this paper. Dr. M.B. confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. In the past 5 years, Dr. M.K. received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018). Dr. M.K. and Dr. A.L. are involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan (2019–2022), Attomol GmbH (2019–2022), GA Generic Assays GmbH (2019–2022), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2022), Lipotype GmbH (2019–2022) and PolyAn GmbH (2019–2022). Dr. M.K. and Dr. A.L. confirm that, to the best of their knowledge, none of the above-mentioned funding sources were involved in the preparation of this paper. The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta AB (Stockholm, Sweden), TheraPanacea (Paris, France), Philips GmbH (Best, The Netherlands); Dr. Sennewald Medizintechnik GmbH (München, Germany), PTW Freiburg (Germany). All other authors have no conflict of interest.